+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Muscular Dystrophy Drug"

Duchenne Muscular Dystrophy - Pipeline Review, H2 2020 - Product Thumbnail Image

Duchenne Muscular Dystrophy - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 413 Pages
  • Global
From
Loading Indicator

Muscular Dystrophy (MD) is a group of genetic disorders that cause progressive muscle weakness and loss of muscle mass. MD is a debilitating condition that affects millions of people worldwide. Central Nervous System (CNS) drugs are used to treat the symptoms of MD, such as muscle weakness, fatigue, and difficulty walking. These drugs can also help to slow the progression of the disease. The Muscular Dystrophy Drug market is a rapidly growing segment of the CNS drug market. It is driven by the increasing prevalence of MD, as well as the development of new treatments and therapies. The market is expected to continue to grow in the coming years, as more treatments become available. Some of the major companies in the Muscular Dystrophy Drug market include Pfizer, Novartis, Merck, and Sanofi. These companies are actively developing new treatments and therapies for MD, and are expected to continue to lead the market in the future. Show Less Read more